Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 34, 2010 - Issue 1
83
Views
15
CrossRef citations to date
0
Altmetric
Original Article

Deferoxamine Versus Combined Therapy for Chelating Liver, Spleen and Bone Marrow Iron in β-Thalassemic Patients: A Quantitative Magnetic Resonance Imaging Study

, , , , &
Pages 95-106 | Received 28 Aug 2009, Accepted 22 Oct 2009, Published online: 01 Feb 2010
 

Abstract

We used magnetic resonance imaging (MRI) to compare the effect of iron chelation on liver, spleen and bone marrow. We examined 21 β-thalassemic patients undergoing deferoxamine (DFO) (9/21) or combined therapy [DFO and deferiprone (L1), 12/21] with two abdominal MRI studies using T1-w/Pd-w/T2*-wGRE and T1-wTSE sequences. Changes in serum ferritin (DF%), and liver, spleen and marrow to paraspinous muscles signal intensity ratios (SI) in T1-wTSE sequence were calculated as D%=[(2ndvalue-1st value)/1st value] ×100%. Negative DF% and positive D(SI)% indicated reduction of iron. Although 17/21 (80.9%) patients demonstrated reduction in ferritin, only 8/21 (38%), 7/21 (33.3%) and 7/21 (33.3%) patients had decreased liver, spleen and marrow iron. Patients undergoing combined therapy showed significantly greater reduction (Student's t-test, p < 0.05) or less increase (t-test, p <0.05) in iron stores. Combined therapy is more effective than DFO for removing and preventing liver, spleen and bone marrow iron accumulation in β-thalassemic patients. Magnetic resonance imaging is valuable for organ-specific monitoring of chelation therapy.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.